lifileucel + pembrolizumab + chemotherapy

**Lifileucel + pembrolizumab + chemotherapy** is a three-component combination therapy used experimentally and investigationally for the treatment of certain advanced malignancies, primarily advanced or metastatic melanoma and non-small cell lung cancer. Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy that harnesses a patient's own immune cells, typically after nonmyeloablative lymphodepleting chemotherapy, to attack cancer. Pembrolizumab is a monoclonal antibody acting as an immune checkpoint inhibitor targeting the programmed death receptor-1 (PD-1), which helps to restore and enhance anti-tumor immune responses. The chemotherapy component generally refers to agents such as cyclophosphamide and fludarabine used for lymphodepletion prior to TIL infusion, but other chemotherapy agents may be used when the regimen is broadened for various cancers. This combination is under active investigation in several clinical trials, particularly for untreated, unresectable, or metastatic melanoma, with emerging data showing promising response rates and durable antitumor effects in immunotherapy-naive patients.[1][2][7][4]

Brand names

KEYTRUDA (pembrolizumab)

Other names

autologous tumor-infiltrating lymphocyte therapy + anti-PD-1 antibody + chemotherapy